All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
UM171-expanded cord blood transplantation for patients with high-risk NDMM: Results from a phase I/II trial
Bookmark this article
|
A single-center, open-label, phase I/II trial (NCT03441958) assessed the safety and efficacy of UM171-expanded CB transplantation in 19 patients aged 18–65 years with high-risk or ultra-high-risk NDMM.1 UM171 is a potent hematopoietic stem cell self-renewal inducer that has been shown to expand CB stem cells and enhance multilineage blood cell recovery.1 Results from this trial were published in Transplantation and Cellular Therapy by Roy et al.1 |
| Key learnings |
| The median expansion of CD34+ cells after 7 days was 49.5-fold, with a median CD34+ cell dose of 4.62 × 106/kg. The median times to achieve ANC of 0.1 x 106/L and 0.5 x 106/L were 6 days and 10.5 days, while the median time to achieve a platelet count ≥20 x 106/L was 36 days. |
| The 1-year cumulative incidences of Grade II–IV and Grade III–IV aGvHD were 68.4% and 5.3%, respectively, while the 2-year incidences of cGvHD and moderate/severe cGvHD were 15.8% and 10.5%, respectively. |
| The 3-year CIR, PFS, OS, and NRM were 36.8%, 47.4%, 68.4%, and 15.8%, respectively. |
| The safety findings were consistent with the known safety profile of CB transplantation. |
| These results indicate that UM171-expanded CB transplantation is a feasible option in patients with high-risk and ultra-high-risk NDMM, showing the potential to reduce GvHD severity while maintaining rapid and effective engraftment. |
Abbreviations: aGvHD, acute graft-versus-host disease; ANC, absolute neutrophil count; CB, cord blood; cGvHD, chronic graft-versus-host disease; CIR, cumulative incidences of relapse; D, day; GvHD, graft-versus-host disease; NDMM, newly diagnosed multiple myeloma; NRM, non-relapse mortality; OS, overall survival; PFS, progression-free survival.
- Roy J, Cohen S, Sauvageau G, et al. A pilot study of UM171-expanded cord blood grafts for tandem auto/allogeneic hematopoietic cell transplant in high and ultra-high-risk myeloma patients. Transplant Cell Ther. Online ahead of print. DOI: 10.1016/j.jtct.2024.10.008
More about...
Your opinion matters
0 votes - 88 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox